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Abstract 
Autophagy is one of the intracellular systems responsible of protein trafficking 
(degradation/recycling) in eukaryotic cells. Whereas this ubiquitous process 
contributes to the cytosolic homeostasis, its deregulation is often associated to various 
pathologies (neurodegenerative diseases, cancer, pathologies with altered 
inflammatory response, etc.). The present paper gives an overview of autophagy, 
especially in inflammation, including mechanisms, regulation, functions and future 
therapies.  
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1. Introduction 
  
Biological mechanisms are controlled by a tight balance of positive and negative 
signals responsible of anabolism and catabolism, also called homeostasis. At the cell level, the 
equilibrium between macromolecule anabolism and catabolism guarantees the cell or the 
tissue integrity. In this context, the unsettling of this functional equilibrium can lead to 
various events including cell death or survival (adequate or inadequate), growth of cancer 
cells, inflammation, or the difficulty of the cells to adapt their metabolism to their nutritional 
environment (1, 2). This review is dedicated to the mechanisms developed by the cells to 
control their homeostasis in physiological and stress conditions. After a brief description of 
the main cellular degradation systems, this paper focuses on the recent knowledge of 
autophagy processes (molecular and regulatory mechanisms) and their roles during 
inflammation.  
 
2. Ubiquitine-proteasome and lysosomal systems represent the main cellular 
mechanisms which control the protein trafficking 
 
To regulate their homeostasis and therefore their survival death, eukaryotic cells 
exhibit two main degradation pathways including ubiquitine-proteasome and lysosomal 
systems (Figure 1). The ubiquitine-proteasome system is associated with the degradation of 
most of the short-lived proteins (3) and clearly appears as a selective catabolic process. 
The most common source of proteasome substrates is mainly cytosolic proteins and 
missfolded proteins from the endoplasmic reticulum, retrotranslocated into the cytosol. Less 
frequently, the proteins can be transferred to the proteasome via endocytosis (4-6) which 
requires a GTPase dynamin-1 activity and includes caveolar and clathrin-mediated 
endocytosis.  
The second system of protein degradation is composed by the lysosomal system in 
which proteins or lipids from both extra- and intra-cellular compartments are delivered to the 
lytic organelles of the cells (lysosomes) and includes in pinocytosis (macro and micro) and 
phagocytosis (see below) (7). The pinocytosis is associated with membrane ruffling and is not 
blocked by specific mutations in dynamin-2 in contrast to caveolar endocytosis (8). The role 
of proteoglycans into the protein degradation has been also widely reported. For instance, 
syndecan-4 has been shown to act as a co-receptor for several growth factors including FGF-2 
(9). Indeed, Tkachenko et al (9) revealed that syndecan-4 uptake, induced by treatment with 
 4 
FGF2, requires the integrity of plasma membrane lipid rafts for its initiation and occurs in a 
clathrin and dynamin independent manner. Thus, two internalization pathways can be 
envisaged depending on the basal expression of syndecans and clathrin (10). De facto, the 
protein degradation is controlled by a tight balance between surface proteoglycans and 
clathrin coated pits (11). The lysosomal system can be also divided into two main pathways 
depending on the origin of the degraded materials. Thus, it is possible to distinguish the 
phagocytosis mechanism mediating the degradation of extracellular materials (Figure 2a) and 
the autophagy processes which lead to the sequestration and the degradation of cytoplasmic 
components including organelles via the lysosomes (12). These different pathways are 
associated with the non-selective degradation of long-lived proteins. Two different types of 
autophagy can be distinguished. The first one, the macroautophagy, usually called as 
autophagy, begins by the formation of cell membrane cisterna of nonlysosomal origin which 
encloses a portion of cytoplasm (with or without organelles) and constitutes an 
autophagosome. Therefore, the membrane of autophagosome fuses with the lysosomal 
membrane and then constitutes the autophagolysosome (acronyme: autolysosome) where 
hydrolytic enzymes degrade the cytoplasmic content (inner membrane, organelles, etc.) 
(Figure 2 b, c) (13, 14). The envelope of autophagosome is then characterized by a double 
membrane. Thus, the macroautophagy garantees the turnover of the most long-lived proteins 
which can be recycled by the cells. A similar sequestration and lysosomal degradation process 
occurs in the second type of autophagy named microautophagy. This process is closely 
related to macroautophagy excepted for two points: (i) transfer of cytosolic components into 
the lysosome is mediated by direct invaginations of the lysosomal membrane; (ii) it represents 
a constitutive mechanism in contrast to macroautophagy which is activated in stress 
conditions (15). The third mechanism of autophagy is a selective degradation system in which 
cytoplasmic subtrates containing a defined motif (a pentapeptide sequence related to KFERQ) 
are specifically recognized and transported by a cytosolic chaperone to the lysosomal 
compartment (16). The molecular chaperone is a complex formed by the constitutive form of 
the heat shock protein of cognate 70 Kda (hsc70), the heat shock protein of 40 kDa (hsp40), 
the hsp90, the hsp70 cochaperone  protein (hip), the hsp70-hsp90 organizing protein (hop) 
and the Bcl2-associated athanogene 1 protein (bag-1) (17). Therefore, this process is called 
chaperone-mediated autophagy and controlled the degradation of a very large list of 
cytoplasmic subtstrates (18). This list includes metabolic proteins (pyruvate kinase, aspartate 
aminotranferase, etc), proteins involved in cell proliferation and differentiation (phospholipid-
binding proteins such as annexin II and IV, or paired box transcription factors) and the 
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lipocalin superfamily of proteins such as α2 microglobulin (19). Thus, the balance between 
the whole of these mechanisms is responsible of a very tightly regulated control of the cellular 
housekeeping. 
 
3. Molecular aspects of macroautophagy: a strongly conserved lysosomal pathway 
 
In the present section, the term autophagy will be used to refer to macroautophagy. As 
autophagy is a strongly conserved lysosomal pathway, its molecular mechanisms have been 
explored using genetic studies on yeast (18, 19), drosophila (20) and Caenorhabditis elegans 
(21) during the past decade. ATP is the first necessary molecule for the cells to perform 
autophagy. Indeed, autophagy sequestration and other post-sequestering events are dependent 
and sensitive to the levels of intracellular ATP (22). Several genes specifically dedicated to 
autophagy have been identified and are called APG for AutoPhaGy (18) and AUT for 
AUTophagocytosis genes (23). To clarify the data available in the literature, the nomenclature 
of the genes involved during autophagy have been recently unified by Klionsky et al (19) who 
proposed the term of ATG for AuTophaGy-related genes. Most of these genes encode 
proteins which exert their activities at the step of autophagosome formation (24), explaining 
the closed association of the Atg proteins with the membranes implicated in autophagy. 
During the step of autophagosome formation, the different proteins (i.e. : Atg12 and Atg5) are 
covalently conjugated by a ubiquitine-like reaction and the very large complex (around 800 
kDa) binds thereafter to the isolation membrane until the formation of autophagosome. Some 
of these proteins exhibit a protease activity such as Atg4B (autophagin-1), involved in the 
cleavage/recycling of Atg8 and then participates to the cell degradation by autophagy (25, 
26). In this context, autophagy implies a specific recruitment of Atg proteins from the cytosol 
to the membranes which initiates the sequestering membranes. The involvement of the ATG 
genes in the autophagosome formation has been clearly demonstrated using deficient 
embryonic stem (ES) cells. Thus, Mizushima et al (27) generated ATG5-/- mouse ES cells 
and demonstrated that the Atg12-Atg5 complex plays a key role in the formation of the 
isolation membrane while these deficient cells showed defects of autophagy pathway. These 
data confirmed those obtained in Saccharomyces cerevisiae (28). Moreover, Mizushima et al 
(27) restored the autophagosome formation after transfection of the deficient ES cells with 
GFP-Atg5 which allowed, for the first time, the visualization of the autophagosome formation 
in real time. If the Atg12-Atg5 complex is essential in the first steps of autophagosome 
formation, several proteins are needed for the late formation of autophagic vacuoles. The 
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small GTP binding protein Rab7 belongs to these proteins (29), as revealed by similar 
experiments as Atg5. Indeed, the role of Rab7 has been addressed by inhibiting Rab7 function 
using RNA interference methods and the overexpression of Rab7 dominant negative. The 
GTP membrane-bound forms of Rab protein recruit specific cytosolic proteins targeting 
vesicles to appropriate sites on the acceptor membranes. Thus, autophagy is regulated by 
GTPase.  
These data demonstrate that macroautophagy regulating mechanisms are controlled by 
a very dense and specific protein network. Therefore, the discovery of these different 
autophagy-related genes and proteins provides new markers for autophagosomes and leads to 
the development of biochemical methods to monitor autophagy activity (30) completing the 
standard method (electron microscopy).  
 
4. Autophagy controls large events of the cell life and probably exerts also many 
other undefined functions  
 
The main function of autophagy is to control protein turnover, cytosolic and organelles 
homeostasis also synonym of cytoplasmic remodeling. In light of its essential role for cell 
survival, microautophagy is usually considered as a constitutive mechanism and 
macroautophagy can be modulated in response to several conditions of stress [deprivation of 
nutrients (31, 32), oxydative stress (33), etc.]. Thus, macroautophagy not only prevents the 
accumulation of intracellular debris, but also allows to recycle cellular components. The best 
mean to stress the cell metabolism consists in nutrient starvation. In these environmental 
conditions, the deprivation of amino acids induces autophagy in vitro after a very short stress 
time (7-8 minutes), acting as a protective mechanism for the cells to guarantee the protein 
levels (31). Kuma et al demonstrated a similar phenomenon in vivo during the early neonatal 
starvation period (32). More precisely, a cross-talk between amino acid signaling and G 
proteins in the regulation of macroautophagy has been described (34), strengthening the 
existence of a cell surface amino acid receptor (35).   
Some evidences from in vivo experiments pointed out the potential implication of 
autophagy mechanisms in inflammation reactions (35, 36). Any tissue aggression by 
infectious agents (bacteria, virus, etc), excess of cell death or proliferation, mechanical stress, 
molecules or drugs, etc lead to the development of a strong organic reaction characterized by 
the chemoattraction and tissue infiltration of immune effectors (macrophages, lymphocytes, 
granulocytes) secreting a large panel of cytokines produced to limit this aggression. The main 
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cells of innate immune reaction include dendritic cells and macrophages which recognize 
specific antigenic structures and function as antigen-presenting cells (APC). Indeed, antigens 
are processed by proteolysis into short peptides which are then presented by major 
histocompatibility complex (MHC) class I an II molecules to T cell receptors (TCR) 
expressed by T lymphocytes, the main effectors of the immune response. In addition, 
macrophages exert many other functions in host defense, in the maintenance of homeaostasis 
(i.e. removal of injured cells), killing infectious agents or malignant cells and thus mediate 
and control the inflammation. MCH class I molecules are thought to present endogenous 
antigens, MCH class II molecules to present peptides derived form exogenous materials (37) 
but the antigen processing for MCH class I or class II are quite different. Most endogenous 
antigens are synthesized on cytosolic ribosomes, processed by proteasomes, enter the 
endoplasmic reticulum where they are associated to MHC class I heavy chain, and thereafter 
traffic to the golgi and to the cell surface. Two pathways have been described for the antigen 
processing for class II MHC molecules. The most prominent processing used endocytosis (via 
receptor-mediated endocytosis such as Fc receptors or recycling via clathrin-coated pits of 
surface proteins) and a minor pathway includes transfer from the golgi to endosome and 
autophagy. Moreover, Nimmerjahn et al recently revealed that the endogenous presentation of 
an epitope derived from the cytosolic protein neomycin phosphotransferase II on MCH class 
II is mediated by autophagy (38), opening new questions on the role of the link between 
cell protein turnover and the immune system. Unfortunatly, whereas autophagy has been 
clearly demonstrated to participate to the antigen processing, its impact on the control of 
immune response needs to be defined and is always controversial (39). 
Lipocalins are a diverse family of proteins with a limited amino acid sequence 
similarity, but with a common tertiary structure (40). Cuervo et al (41) showed the 
accumulation in lysosomes of  α2 microglobulin which belongs to the lipocalin superfamily 
via a chaperone mediated autophagy mechanism. The human homologuous of rat α2 
microglobulin is the human neutrophil gelatinase-associated lipocalin (NGAL) (40). In light 
of its cellular induction in macrophages, LPS- or TNFα- activated hepatocytes and its intense 
synthesis in inflamed colon, NGAL appears as a modulator of inflammatory response. NGAL 
would be produced to limit the tissue damages inducible by an excessive inflammatory 
reaction.  This hypothesis is strengthened by the inhibitory effect of the NGAL preincubation 
on neutrophils (40). The sequestration and degradation of lipocalins by autophagy clearly 
appears as modulation process of the inflammation reaction intensity (i.e. biological 
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equilibrium between pro-inflammation reaction in response to pathogens and anti-
inflammatory reaction to limit the tissue damages). 
Inflammatory process is also characterized by an extensive production of growth 
factors and cytokines which modulate vascular permeability, leukocyte infiltration and 
activation, and production of acute phase proteins. The control of autophagic cell death by 
growth factors (42-44) has been recently proved by Lum et al (45). Indeed, using growth 
factor-dependent cells from Bax/Bak-deficient mice, these authors demonstrated that 
following growth factor withdrawal, Bax/Bak-deficient cells activate autophagy, undergo 
progressive atrophy, and ultimately succumb to death. Furthermore, cells respond to growth 
factor readdition by rapid restoration of their metabolism and subsequently recovery of their 
original size and proliferation rate. Such process explains in part the equilibrium between 
apoptosis and autophagy (46, 47). Whereas the most of apoptosis mechanisms involve 
caspase activation, autophagy is a caspase-independent mechanism process involving the 
lysosome pathway. Moreover, in both cases, the inhibition of caspases, proteasome or 
lysosome reduce cell death. In this context, autophagy is a strategy for survival in response to 
apoptosis which incurably leads to cell death. Thus, extracellular signals tightly regulate 
autophagy and cell death. Similar phenomenon takes place in inflammatory processes and 
participates to death control of injured cells or infected cells. Whereas cytokines can reduce 
autophagy, some of them induce it in defined circumstances. This is the case of the tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL), one member of the TNF-α 
surperfamily strongly involved in inflammation (48). Similarly, IFN-γ induced cell death by 
autophagy through a mechanism dependent of Atg5 and its interaction to the Fas-Associated 
protein with Death Domain (FADD) (49). Autophagy is then sensitive to a great number of 
growth factors that transduce a variety of signalling molecules (ERK1/2, PI3K, GTPase, etc). 
In fine, the signals are transduced to a common target which occupies a privileged position in 
autophagic process. The kinase TOR (Target Of Rapamycin) plays this role in association 
with its downstream signalling molecules, the Atg kinases (50). In this context, Rapamycin 
which induces autophagy through the inhibition of TOR, can favor the clearance of 
aggregating proteins and then may be helpful in ameliorating the response to inflammation. 
α1-antitrypsin is the archetype of the Serpin supergene family and is the main inhibitor of 
destructive neutrophil protease (elastase, cathepsin G, proteinase 3). This glycoprotein, 
considered as an acute-phase reactant, is secreted by liver cells and its concentration increases 
during the host response to inflammation. Teckman and Perlmutter demonstrated that 
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autophagosomes appear in response to α1-antitrypsin induction and its accumulation in the 
endoplasmic reticulum (51). This study suggests that the autophagic response is induced to 
protect liver cells from the toxic effect of aggregated α1-antitrypsin retained in endoplasmic 
reticulum (52).  
Recently, Shao et al showed that histone deacetylase inhibitors can induce both 
mitochondria mediated-apoptosis and caspase-independent autophagic cell death (53).  
Moreover, Kiffin et al demonstrated the activation of chaperone-mediated autophagy during 
oxidative stress which clearly occurred during inflammation through i.e. the accumulation of 
oxidatively damaged proteins (54).  Similarly, histone deacetylase inhibitors reduced NO 
production by peritoneal macrophages, IL-12 secretion by monocytes, without alterations of 
T-cell-receptor-stimulated IFN-γ production by peripheral blood mononuclear cells (55). 
These data strengthen the therapeutic potential of histone deacetylase inhibitors as potent 
contenders for anti-inflammatory drugs (56). 
 
5. Autophagy in infectious diseases is induced by microorganisms but does not 
succeed in the eradication of the bacterial or viral infections 
 
Microorganism infections lead to the development or local of systemic inflammatory 
processes. The degradation of undesirable invading microbes, essential for cell survival, 
involves autophagy. Autophagy appears as a defense mechanism inhibiting the survival of 
microorganisms (57, 58). Unfortunatly, intracellular bacteria and viruses must survive the 
antimicrobial responses of their hosts to replicate successfully. Thus, although 
microorganisms are sensitive to autophagic destruction, pathogens evolved strategies to avoid 
autophagy (56). After intracellular infection, they modulate the host phagosome to establish 
an intracellular niche for their survival and replication (59). In many cases, autophagy is 
dispensable for intracellular replication (60), inducing the cell death and the propagation of 
the pathogens (61). Other pathogens such as Shigella were found to escape to the autophagy 
process by secreting specific molecules (62). The identification of interactions occurring 
between microorganisms and eukaryotic cells is then the key point to develop novel drugs 
with antimicrobial activities (63).  
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6. New therapeutic approaches and conclusions 
Whereas autophagy appears as a control mechanism of cell protein homeostasis, it also 
modulates numerous other activities. Particularly, it is likely that autophagy takes part in cell 
protection against toxicity caused by abnormal proteins or protein accumulations by helping 
their degradation (Figure 2d, 64), thereby allowing to adapt the immune and cellular 
responses to the inflammation stress (Figure 2e). Finally, autophagy may result in cell death 
or/and may correspond to a mechanism of cell survival in stress conditions. In this context the 
pharmacomodulators of apoptosis affect autophagy processes. Several drugs modulating the 
different types of cell death are being explored at the preclinical and clinical levels and are 
promising in the treatment of infectious, cancerous or degenerative pathologies associated 
with inflammatory process (65-68). Some of them are in clinical development or are approved 
by the FDA (66). Thus, mTOR inhibitors induce autophagy and then inhibit the 
development of solid tumors (68). Similarly, histone deacetylase induce cell death through a 
mitochondria-mediated apoptosis and a caspase-independent autophagic cell death and then 
represent a very promising new drug class for the treatment of diseases associated with 
apoptotic defects (53). These agents act probably as true blockers of cell death and through 
their anti-inflammatory effects. The identification of molecules involved in autophagy will 
help a better understanding of this cellular mechanism and lead to the development of new 
therapeutic strategies.  
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FIGURE LEGENDS 
Figure 1: Schematic diagram of the main cellular mechanisms controlling the protein 
degradation pathways in eukaryotic cells 
 
Figure 2: Morphological feature of phagocytose and autophagy in eukaryotic cells.  (a) 
Phagocytose of a polynuclear (white arrow) by  a macrophage; (b, c) typical feature of 
autophagy (white and black arrows) into macrophages in culture; (d) macrophage in culture 
degrading calcium phosphate ceramic, autophagic vesicle (white arrow) (containing cell 
endogenous materials (black arrow) and exogenous materials (black arrow head). Original 
magnification: (a, c) X 7,500; (b) X 5,000;  (d) X 11,000; (e) cellular/molecular protagonists 
involved in autophagy associated with inflammation and the main processes controlled by 
autophagy during inflammatory process. 
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Molecular regulators of inflammation: 
cytokines, growth factors
Cellular immune effectors: macrophages, 
granulocytes, lymphocytes
- MCH class I/II processing: control of the antigen presentation
- Sequestration and degradation of lipocalins: limitation of the tissue damages 
inducible by an excessive inflammatory reaction
- Equilibrium between apoptosis-autophagy: strategy for survival in response to 
apoptosis
- Protection of liver cells: i.e. from the toxic effect of aggregated α1-antitrypsin
retained in endoplasmic reticulum
- Defense mechanism inhibiting the survival of microorganisms
Processes controlled by autophagy
Key molecules of autophagy: mTOR and Atg kinases 
(+ acute phase proteins)
Survival Cell death
Autophagy in inflammatione
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